Trial Profile

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Domvanalimab (Primary) ; Quemliclustat (Primary) ; Zimberelimab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ARC-21; EDGE-Gastric
Sponsors Arcus Biosciences

Most Recent Events

19 Mar 2025 Status changed from recruiting to active, no longer recruiting.
25 Feb 2025 According to a Arcus Biosciences media release, Overall survival data from the Phase 2 EDGE-Gastric study is expected to be presented in the fall of 2025.
06 Nov 2024 According to a Arcus Biosciences media release, Overall survival data from this study is expected to be presented in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com